克尔来福®

克尔来福® CoronaVac®
releaseTime:2022-01-29
articleSource:SINOVAC

克尔来福®简介

CoronaVac®

克尔来福® 是世界上使用量最大的中国新冠疫苗(截止 2022 1 29 日,全球供应量超27亿剂,全球接种量超23亿剂,占全球供应和接种总量的23%,占中国供应全球总量的51%)。

CoronaVac®  is one of the most widely used COVID-19 vaccines around the world. As of 29th  Jan 2022, 2.7 billion doses of the vaccine have been delivered worldwide while 2.3 billion doses of the vaccine have been administrated 23% of total global supply and vaccination, accounting for 51% of Chinese Covid-19 vaccine global supply. 

克尔来福® 目前是使用于最低年龄的新冠疫苗(3岁),   截止至 2022 1 10 日,已经为中国 3 17 岁儿童接种超过 2.48 亿剂。

CoronaVac®  has been approved to be used as low as 3 years old or above in some countries. As of 10th  Jan 2022, over 248 million CoronaVac doses have been administered in Chinese children aged 3 to 17.

克尔来福® 使用灭活疫苗技术,是目前安全性最高的疫苗生产技术之一,该技术已经使用了一个多世纪。

CoronaVac®  is an inactivated COVID-19 vaccine, which is one of the safest vaccines and vaccine platforms that had been used for more than a century. 

使用疫苗最关键的作用是控制重症及死亡,而克尔来福® 的保护效力在这方面很有竞争力。

The most critical aim of using vaccines is to reduce the number of severe cases and fatal cases. CoronaVac’s  vaccine effectiveness  is comparable to other Covid 19 vaccines.

科兴拥有最集中、最稳定的克尔来福® 生产体系,能及时、大量、稳定供应疫苗。

Sinovac has the most integrated and stable production and quality control system which can support the high demand and stable supply of vaccines promptly. 

克尔来福® 可以在特殊人群中诱发较好的免疫原性并表现出良好的安全性,包括老年人,儿童和青少年,孕妇,免疫功能低下患者,慢性病患者,器官移植受者等。

CoronaVac®  could induce  good  immunogenicity and perform a good safety profile among special groups of the population, including the elderly, children and adolescents, pregnant women, immunocompromised patients, people with chronic diseases, organ transplant recipients, and so on.

接种三剂克尔来福® 有望降低对Omicron变异株感染所致的重症风险 [2]

Sinovac COVID-19 vaccines protect against "severe hospitalization" caused by the Omicron variant, the United Arab Emirates-based news outlet The National reported on 4th  Jan 2021, quoting a World Health Organization (WHO) expert as saying [1] .

新型冠状病毒灭活疫苗—克尔来福®

COVID-19 Vaccine (Vero Cell), Inactivated - CoronaVac®

2020年6月24日 率先在中国获批紧急使用。

It was first approved for emergency use in China on June 24, 2020.

2021年2月5日 在中国首批获附条件上市。

It was the first batch of COVID-19 vaccine marketed conditionally in China on February 5, 2021.

2021年4月1日 建成20亿剂年产能,日产能达1000万剂以上。

The annual production capacity reached 2 billion doses on April 1, 2021, with a daily production capacity of more than 10 million doses.

2021年6月1日 正式列入世界卫生组织紧急使用清单。

It was officially listed in the WHO Emergency Use Listing on June 1, 2021.

截至2021年6月24日全球累计发货超9亿剂,全球累计接种超7亿剂,全球接种新冠疫苗每4剂就有1剂是克尔来福®

As of June 24, 2021, more than 900 million doses of vaccines had been delivered worldwide, and more than 700 million doses of vaccines had been administered worldwide. One out of every four doses of COVID-19 administered globally is CoronaVac® .

发往全球

2021.06.08 乌拉圭真实世界保护效果研究初步结果。

2021.06.08, Preliminary real-world study on the efficacy of vaccine in Uruguay.

2021.05.31 巴西塞拉纳小镇保护效果研究。

2021.05.31, Real-world study on the efficacy of vaccine in a small town in Brazil, Serrana.

2021.05.17 智利真实世界保护效果研究。

2021.05.17, Real-world study on the efficacy of vaccine in Chile.

2021.04.30 巴西真实世界老年人保护效果研究。

2021.04.30, Real-world study on the efficacy of the vaccine in the elderly in Brazil.

2021.04.29 智利真实世界安全性研究结果。

2021.04.29, Real-world study on the safety of the vaccine in Chile.

2021.02.05 克尔来福®Ⅲ期临床研究结果公布,符合WHO要求。

2021.02.05, Results of Phase III clinical study of CoronaVac®  were published, conforming to WHO requirements.

2021.02.03《柳叶刀感染性疾病杂志》发表克尔来福 ®老人组Ⅰ/Ⅱ期临床研究论文:在60岁及以上老人中显示安全有效。

2021.02.03, A paper on Phase I/II clinical study of CoronaVac®  in the elderly group was published in the Lancet Infectious Diseases: showing the safety and efficacy in patients aged 60 years and above.

2020.11.17《柳叶刀感染性疾病杂志》发表克尔来福®成人组Ⅰ/Ⅱ期临床研究论文:在18~59岁岁及以上老人中显示安全有效。

2020.11.17, A paper on Phase I/II clinical study of CoronaVac ®  in the adult group was published in the Lancet Infectious Diseases: showing the safety and efficacy in patients aged 18~59 years and above.

2020.06.14 克尔来福 ®I/Ⅱ期临床研究揭盲:初步结果显示该疫苗具有良好的安全性和免疫原性。

2020.06.14, Unblinding of Phase I/II clinical study on CoronaVac® : preliminary results show that the vaccine has favorable safety and immunogenicity.


[1]   https://www.thenationalnews.com/coronavirus/2022/01/04/vaccines-like-sinopharm-sinovac-protect-against-severe-hospitalisation-from-omicron-who/  

[ 2]   Wang, Kang, et al. "Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants."  Nature (2022): 1-1.